Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Wohl

Showing results (121-130 of 185) with videos related to

Pageof 19
Sort By:
Clinical Pharmacology and Therapeutics|July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 InfectionRachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
PLOS Global Public Health|March 27, 2023
It takes more than a machine: A pilot feasibility study of point-of-care HIV-1 viral load testing at a lower-level health center in rural western UgandaRoss M Boyce, Ronnie Ndizeye, Herbert Ngelese, et al.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 10, 2017
Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT TrialDavid A Wohl, Carol E Golin, Kevin Knight, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
AIDS Research and Human Retroviruses|March 13, 2020
Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366Karine Dubé, Lara Hosey, Kate Starr, et al.
AIDS Research and Human Retroviruses|October 15, 2019
The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral TherapyKarine Dubé, Shadi Eskaf, David Evans, et al.
The Journal of Infectious Diseases|April 17, 2018
Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus DiseaseJerry F Brown, John M Dye, Sam Tozay, et al.
Pageof 19

Showing results (121-130 of 185) with videos related to

Sort By:
Pageof 19
Clinical Pharmacology and Therapeutics|July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 InfectionRachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
PLOS Global Public Health|March 27, 2023
It takes more than a machine: A pilot feasibility study of point-of-care HIV-1 viral load testing at a lower-level health center in rural western UgandaRoss M Boyce, Ronnie Ndizeye, Herbert Ngelese, et al.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 10, 2017
Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT TrialDavid A Wohl, Carol E Golin, Kevin Knight, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
AIDS Research and Human Retroviruses|March 13, 2020
Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366Karine Dubé, Lara Hosey, Kate Starr, et al.
AIDS Research and Human Retroviruses|October 15, 2019
The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral TherapyKarine Dubé, Shadi Eskaf, David Evans, et al.
The Journal of Infectious Diseases|April 17, 2018
Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus DiseaseJerry F Brown, John M Dye, Sam Tozay, et al.
Pageof 19